Sio Gene Therapies Inc. Common Stock
SIOX
SIOX was delisted on the 22nd of March, 2023.
62 hedge funds and large institutions have $39.7M invested in Sio Gene Therapies Inc. Common Stock in 2020 Q4 according to their latest regulatory filings, with 27 funds opening new positions, 16 increasing their positions, 8 reducing their positions, and 15 closing their positions.
100% more repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 8
80% more first-time investments, than exits
New positions opened: 27 | Existing positions closed: 15
27% more call options, than puts
Call options by funds: $1.71M | Put options by funds: $1.35M
24% more funds holding
Funds holding: 50 → 62 (+12)
25% less capital invested
Capital invested by funds: $52.7M → $39.7M (-$13M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCMNY
Rubric Capital Management (New York)
New York
|
+$5.46M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.21M |
| 3 |
SCM
Sio Capital Management
New York
|
+$2.58M |
| 4 |
Morgan Stanley
New York
|
+$1.02M |
| 5 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
+$801K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$5.33M |
| 2 |
CA
Corriente Advisors
Fort Worth,
Texas
|
-$4.04M |
| 3 |
Renaissance Technologies
New York
|
-$2.04M |
| 4 |
Two Sigma Investments
New York
|
-$1.42M |
| 5 |
IC
Ikarian Capital
Dallas,
Texas
|
-$820K |
SIOX Hedge Fund Activity: Q4 2020 in Review
62 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Sio Gene Therapies Inc. Common Stock (SIOX) for Q4 2020, worth a combined $39.7M — down 25% from $52.7M a quarter earlier.
Buyers outnumbered sellers: 27 funds opened new SIOX positions and 15 closed out — a net gain of 12 holders — while 16 added to existing stakes and 8 trimmed.
The largest buyer was Rubric Capital Management (New York), adding an estimated $5.46M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $5.33M sold.
- 62 institutional investors held Sio Gene Therapies Inc. Common Stock (SIOX) as of Q4 2020, up from 50 in Q3 2020.
- Funds reported $39.7M of Sio Gene Therapies Inc. Common Stock stock for Q4 2020, down 25% quarter-over-quarter.
- 27 funds opened new Sio Gene Therapies Inc. Common Stock positions in Q4 2020 and 15 closed out, a net change of +12 holders.
- The largest Sio Gene Therapies Inc. Common Stock buyer in Q4 2020 was Rubric Capital Management (New York), an estimated $5.46M added.
- The largest Sio Gene Therapies Inc. Common Stock seller in Q4 2020 was Sphera Funds Management, an estimated $5.33M sold.
Based on aggregated 13F filings for Q4 2020.